BillionaireNet
Rothbaum
Wayne Rothbaum
Rank #1509
UNITED STATESFinance & InvestmentsBiotech investing

Wayne Rothbaum

Net Worth
$2.64B
-0.07% (24h)
Wayne Rothbaum, a prominent figure in the biotech industry, is a self-made billionaire known for his strategic investments. His career began at The Carson Group before founding Quogue Capital in 2001. Rothbaum's primary source of wealth is biotech investing, and he is recognized for his significant role in the development of cancer therapies. He is currently the Executive Chairman of Kartos Therapeutics and Telios Pharma and has held leadership positions in Iovance Biotherapeutics, where he is also the largest shareholder. Rothbaum's net worth is estimated at $2.6 billion, and he is a notable figure in the healthcare industry.

The Full Dossier

Early Life and Education

Wayne P. Rothbaum was born and raised in the United States. He graduated Phi Beta Kappa from Binghamton University in 1990 with a dual major in political science and psychology. He furthered his education by earning a Master's degree in international economics from The George Washington University.

Career and Rise to Success

Rothbaum began his career at The Carson Group, a strategic consulting firm, where he managed its life sciences practice and boutique investment bank Evolution Capital. Following The Carson Group's sale to Thomson Reuters in 2001, Rothbaum founded Quogue Capital, a life sciences investment fund. Through Quogue Capital, he has invested in numerous private and public life sciences companies.

In 2012, Rothbaum co-founded and became the largest investor in Acerta Pharma, a cancer drug developer, which developed Calquence, a drug approved to treat forms of lymphoma and leukemia. AstraZeneca acquired 55% of Acerta Pharma in 2016 for $4 billion and agreed to acquire the remainder for nearly $2.5 billion. Rothbaum is currently the executive chair of Kartos Therapeutics, which he co-founded in 2016, and Telios Pharma, co-founded in 2019. Rothbaum also led a restructuring of Iovance Biotherapeutics, where he is a board member and the largest shareholder.

Key Business Strategies

Rothbaum's success is attributed to his strategic investment approach in the biotech sector. He invests his own funds, and his strategy involves identifying promising companies and technologies, focusing on innovative cancer therapies.

Philanthropy

Wayne Rothbaum has been recognized for his philanthropic efforts. He donated $300 million to SUNY Binghamton for a sports complex and scholarships, as well as to Ohio State University to build housing for cancer patients.

Career Timeline

2019

Cofounded Telios Pharma

Cofounded Telios Pharma.

2016

Cofounded Kartos Therapeutics

Cofounded Kartos Therapeutics.

2012

Cofounded Acerta Pharma

Cofounded and became the largest investor in Acerta Pharma, a cancer drug developer.

2001

Founded Quogue Capital

Founded Quogue Capital, a life sciences investment fund.

Philanthropic Impact

Education$300M

SUNY Binghamton Donation

Donated to SUNY Binghamton for a sports complex and scholarships.

HealthcareUnknown

Ohio State University Donation

Donated to Ohio State University to build housing for cancer patients.

Wealth Trajectory